The senate passed new legislation that would empower the FDA to monitor the safety and efficacy of drugs already on the market. Currently the FDA’s oversight is primarily limited primarily to pre-market approval, including the so-called clinical trial process. Of particular interest is that under this plan the FDA would systematically track adverse drug reactions, the cause of up to 100,000 deaths annually in the United States.
News Items
09 May 2007 |
Senate Approves Tighter Policing of Drug Makers
19 Apr 2007 |
Gene plays key role in embryonic, adult stem cells
One of the defining features of stem cells is their ability to self-renew, or make carbon copies of themselves while remaining in an undifferentiated state. Now researchers have discovered a key gene which enables cells to remain in this undifferentiated state.
11 Apr 2007 |
Stem Cell Transplant Resets Immune System in Type 1 Diabetes Patients
A Northwestern researcher has used adult stem cell injections to reset the immune systems of patients with early-onset Type 1 diabetes. After the therapy, patients no longer needed to take insulin for up to 35 months.
05 Apr 2007 |
More Govs Boost Stem Cell Research
The political battles over stem cell research are heating up once again, but it’s the states which are moving forward, not the federal government.
